Skip to main content

Table 2 A summary of previous reports of SR in lung cancer

From: Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature

Authors Age Gender Staging Histology Degree of Remission Follow-Up Duration Relapse or Death Potential Trigger
Identified
Previous / Subsequent Treatment / Outcomes Details
Primary Nodes Metastases
Jeong et al. 2019 [24] 64 M T1c NX MX Squamous cell carcinoma Complete Not applicable Not applicable 16 Local relapse Biopsy • Neoadjuvant chemo on relapse
• Lobectomy (ypT0 N2)
• Adjuvant chemo + RT
• Unknown follow-up
Matsui et al. 2018 [25] 56 F T1a N2 M0 Squamous cell carcinoma Partial None Not applicable 12 No Biopsy • Lobectomy (ypT1a N2)
• No adjuvant treatment
• Disease-free at 1 year
Ooi et al. 2018 [26] 77 M T3 N1 M0 Not otherwise specified Partial Complete Not applicable 24 No None • Surveillance ongoing
Ariza-Prota et al. 2018 [19] 82 M T3 N3 M1c Squamous cell carcinoma Partial Partial Complete 12 No Biopsy • Palliative thoracic RT
• Death 1 year later (MI)
Esplin et al. 2018 [27] 57 M T1b N0 M0 Squamous cell carcinoma Partial Not applicable Not applicable Not reported Not reported Biopsy Not reported
Miyoshi et al. 2017 [28] 80 M Not reported Adenocarcinoma Partial Not applicable Not applicable 31 No Biopsy • Surveillance ongoing
Marques et al. 2017 [29] 75 M T1b N0 M0 Adenocarcinoma Complete Not applicable Not applicable 36 No Biopsy • Surveillance ongoing
Lopez-Pastorini et al. 2015 [30] 76 M T3 N2 M0 Large cell carcinoma Partial Partial Not applicable 84 No Biopsy • Surveillance ongoing
Choi et al. 2013 [31] 71 M Not reported Squamous cell carcinoma Partial Not applicable Not applicable Not reported No Tuberculosis • Surveillance ongoing
Kappauf et al. 1997 [32] 61 M TX NX M1b Adenocarcinoma Not Applicable Not applicable Complete 78 No Biopsy • Lobectomy 7/12 earlier
Park et al. 2016 [33] 79 M TX NX M1a Squamous cell carcinoma Partial Partial Partial 14 No Ginseng Not reported
Ogawa et al. 2015 [34] 65 M TX NX M1c Not otherwise specified Partial Partial Partial Not reported Not reported Biopsy • Palliative RT given for MSCC after SR had began
Kwint et al. 2015 [35] 80 M T2a N3 M1b* Not otherwise specified Partial Partial Complete 6 No None Not reported
Cafferata et al. 2004 [36] 68 M T1c N0 M0 Adenocarcinoma Complete Not applicable Not applicable 48 No None Not reported
Chung et al. 2015 [37] 67 M T4 N0 M1b Squamous cell carcinoma Partial Not applicable Not reported 13 No Herbal medicine Not reported
Menon et al. 2015 [38] 44 M T1b N0 M1c Not otherwise specified Partial Not applicable Complete 60 No HAART • WBRT at diagnosis
• HAART adherence increased
Hwang et al. 2013 [39] 62 M T2a N3 M0 Not otherwise specified Complete Partial Not applicable 14 No None • Declined all treatment
Mizuno et al. 2011 [40] 62 M T1b N0 M0 Large cell carcinoma Complete Not applicable Not applicable 6 Distant Relapse Biopsy/Surgery • Palliative chemo
Nakamura et al. 2009 [41] 71 M T4 N0 M0 Adenocarcinoma Disease Progression Not applicable Complete 34 No Immunological • Palliative RT to hilum
Pujol et al. 2007 [42] 75 F Localised but no staging Squamous cell carcinoma Complete Not applicable Not applicable 18 No Anti-Hu paraneoplastic syndrome • Plasmapheresis
Miyazaki et al. 2007 [43] 74 M TX N0 M1b Adenocarcinoma None Not applicable Complete 35 No None • Received radical RT to the primary eventually
Furukawa et al. 2011 [44] 56 M T1 N0 M0* Squamous cell carcinoma Partial Not applicable Not applicable 2 No Bullous disease • Resected after 2 months
Gladwish et al. 2010 [45] 84 F T3 N3 M0 Squamous cell carcinoma Partial Partial Not applicable 12 No None • No treatment accepted
Yoon et al. 2019 [46] 74 F T3 N1 M0 Not otherwise specified Partial Partial Not applicable 9 No Herbal medicine • Progressed through 6 lines of palliative chemo
• SR noted one year following cessation of chemo
Leo et al. 1999 [47] 59 M T1c N1 M0 Large cell carcinoma Complete Not applicable Not applicable 4 No Inadequate vasculature • Appearance of LN during SR
• Lobectomy, bronchial sleeve resection and LN sampling performed
Tomizawa et al. 2014 [48] 85 F T1c N0 M0 Large cell carcinoma Partial Not applicable Not applicable 13 Local relapse Immunological • SR ended on commencing glucocorticoids for inflammatory arthritis
• Lobectomy on relapse